Observational studyRespiratory research2021
Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma.
Observational study in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review.Pulmonary therapy · 2026Review
- Development and validation of a long-term survival prediction model for older adults with asthma.Archives of public health = Archives belges de sante publique · 2026Article
- Dupilumab improves long-term asthma control in German patients with severe asthma: Real-world data.Allergologie select · 2026Article
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
- Mortality Among Adults with Subspecialist-Treated Severe Asthma: A Descriptive Analysis from the Observational CHRONICLE Study.Journal of asthma and allergy · 2026Article
- Short-Term Prognosis in Acute Asthma Exacerbations: A Comparative Evaluation of Machine Learning Models Using Spirometry and Tracheal Respiratory Sound Analysis.International journal of general medicine · 2026Article
- Occupational airborne exposures and asthma mortality - examining asthma as the underlying and contributing cause of death.BMC pulmonary medicine · 2025Article
- Hospitalisations for bronchiectasis compared to COPD and asthma in the USA.ERJ open research · 2025Article
- Predictors of mortality and hospitalised exacerbations in obstructive airway diseases.ERJ open research · 2025Article
- Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study.Frontiers in allergy · 2025Article
- Eosinophil count testing in patients with asthma varies by healthcare provider type in the US: a retrospective study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Dietary antioxidant and inflammatory potential in asthmatic patients and its association with all-cause mortality.Nutrition journal · 2024Article
- Evaluation of adherence to guideline-directed therapy and risk factors for exacerbation in mild asthma: a retrospective chart review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- The economic burden of asthma prior to death: a nationwide descriptive study.Frontiers in public health · 2024Observational
- Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes.Frontiers in medicine · 2024Review
- Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.The World Allergy Organization journal · 2023Article
- Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.ERJ open research · 2023Article
- Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.Journal of asthma and allergy · 2023Article
- Percent Recovery Index Predicts Poor Asthma Control and Exacerbation in Adults.Journal of asthma and allergy · 2023Article
- Asthma and Tobacco Smoking.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe aimed to explore long-term predictors of severe exacerbations and mortality in adults with well-characterised asthma. STUDY DESIGN AND
methodsAdults (aged ≥ 15) with an objectively verified diagnosis of asthma were recruited from a Danish respiratory outpatient clinic between 1974 and 1990. All individuals were followed in Danish registries for vital status, hospital admissions for asthma and cause of death until end of 2017. Predictors of exacerbations were obtained from a repeated measures model. Standardised mortality rates (SMR) for all-causes were compared with the Danish background population. Hazard ratios for mortality were obtained from a cox proportional hazards model in a two-step process.
resultsAt baseline, the cohort comprised 1071 patients (mean age 38, SD 16, 61% women), of whom 357 (33%) died during follow-up, with 93 (26%) dying from asthma (primary diagnosis). We found an SMR of 1.24 (95% CI 1.11-1.37, p < 0.001) for all-cause mortality. Baseline predictors for asthma-related death and repeated severe exacerbations were increasing age, ever smoker, FEV
conclusionsMarkers of poor asthma control, including high use of SABA, are predictors of long-term exacerbation rate and mortality over 30 years in patients with well-characterised asthma. Improving asthma control, including lung function and reducing use of reliever medication, is vital for improving the long-term outcome of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.